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At a glance commentary 
Earlier we performed dendritic cell-based immunotherapy in a preclinical tumor 
model as well as in patients with mesothelioma. These studies showed that 
administration of whole tumor cell lysate-pulsed dendritic cells is feasible and that 
it can induce distinct immune responses and antitumor responses. However, 
some hurdles need to be overcome for improving clinical efficacy. Alleviation of 
the tumor-induced immune suppression could improve the efficacy of 
immunotherapy. In this study, 3 to 5 injections of tumor lysate-loaded monocyte-
derived mature dendritic cells were administered to five patients after 
pemetrexed-cisplatin or pemetrexed-carboplatin treatment and five patients after 
induction chemotherapy followed by pleurectomy/decortication. Simultaneously, a 
metronomic dose of cyclophosphamide (CTX) was administered to these patients 
to investigate its potency to overcome immunosuppression by regulatory T cells 
(Treg). We showed that 1-week of CTX significantly reduced the mean Treg 
percentage of total CD4 cells in peripheral blood, but an elevated Treg 
percentage initially was only found in a minority of patients. Furthermore, we 
demonstrated the safety and feasibility of this combination therapy in 
mesothelioma patients and found sustained tumor control. 
 
Online data supplement 
This article has an online data supplement, which is accessible from this issue's 
table of content online at www.atsjournals.org 
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Abstract  
Rationale: We demonstrated before that autologous tumor lysate-pulsed dendritic 
cell-based immunotherapy in patients with malignant pleural mesothelioma is 
feasible, well-tolerated, and capable of inducing immunological responses against 
tumor cells. In our murine model we found that reduction of regulatory T cells with 
metronomic cyclophosphamide increased the efficacy of immunotherapy.  
Objectives: To assess the decrease in number of peripheral blood regulatory T 
cells during combination therapy of low-dose cyclophosphamide and dendritic cell 
immunotherapy and to determine the induction of immunological responses with 
this treatment in mesothelioma patients.  
Methods: Ten malignant pleural mesothelioma patients received metronomic 
cyclophosphamide and dendritic cell-based immunotherapy. During the treatment, 
peripheral blood mononuclear cells were analyzed for regulatory T cells and 
immunological responses. 
Measurements and Main Results: Administration of dendritic cells pulsed with 
autologous tumor lysate combined with cyclophosphamide in mesothelioma 
patients was safe, the only side effect being moderate fever. Dendritic cell 
vaccination combined with cyclophosphamide resulted in radiographic disease 
control in eight of the ten patients. Overall survival was promising, with seven out 
of ten patients having a survival of ≥24 months and two patients still alive after 50 
and 66 months. Low-dose cyclophosphamide reduced the percentage of 
regulatory T cells of total CD4 cells in peripheral blood from 9.43 (range 4.34-
26.10) to 4.51 (range 0.27-10.30) after 7 days of cyclophosphamide treatment 
(P=0.02).  
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Conclusions: Consolidation therapy with autologous tumor lysate-pulsed dendritic 
cell-based therapy and simultaneously reducing the tumor-induced immune 
suppression is well-tolerated, and shows signs of clinical activity in mesothelioma 
patients.  
 
Abstract word count 246 (max 250)  
Keywords: immunotherapy, regulatory T cell, tumor microenvironment, 
immunosuppression, pleurectomy/decortication  
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Introduction 
 
Malignant pleural mesothelioma (MPM) is a highly lethal neoplasm with 
limited treatment options. Despite aggressive treatments with combinations of 
surgery, chemotherapy, and radiotherapy, it is almost inevitably accompanied 
with recurrences. Remarkably, however, long-term survivors do occur either with 
or without any treatment(1, 2). This may be explained by germline mutations, in 
which patients with BAP1 mutations recently were found to have an overall 7-fold 
increased long-term survival(3). Also, the role of the immune system in 
mesothelioma has provided new insights, which begin to explain the differences 
in the complex behavior of individual tumors and also uncover new possibilities 
for treatment(4). 
Earlier we performed a phase I clinical trial using active immunotherapy in 
ten mesothelioma patients, who were treated with chemotherapy followed by 
three vaccinations of autologous tumor lysate-pulsed monocyte-derived dendritic 
cells (DC)(5). Results showed that these vaccines were well tolerated without 
systemic toxicity, and radiographic tumor responses were established. We were 
also able to detect distinct immune and cytotoxic T lymphocyte antitumor activity 
in the peripheral blood of these patients.  
It is now well recognized that the efficacy of immunotherapy is influenced 
by the immunosuppressive environment created by the tumor(6). The presence of 
this immunosuppressive environment hampers attempts at harnessing the 
potency of the immune system. An increasing number of immunosuppressive 
factors and cells are reported in malignant diseases. We, among others, have 
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established that regulatory T-cells (Tregs) play a major role in mesothelioma by 
contributing to an impaired T-cell function(7, 8).  
Clinical studies have shown that low-dose cyclophosphamide (CTX) 
induces beneficial immunomodulatory effects in the context of active or adoptive 
immunotherapy by reducing the number of Tregs and their functionality(9, 10). In 
our murine model of mesothelioma we found that prolonged (metronomic) low-
dose CTX augmented the anti-tumor effects of DC vaccines and increased 
survival via a reduction of the number of Tregs(11).  
In the present study, we investigated whether these preclinical findings 
could be confirmed in patients. Ten patients with MPM who had previously been 
treated with chemotherapy or chemotherapy and debulking surgery were treated 
with CTX combined with DC-based immunotherapy as a consolidation/adjuvant 
treatment. The aim was to establish a reduction in the number of circulating Tregs 
by CTX and to determine the safety of immune therapy in these patients. We 
found that CTX combined with DC-immunotherapy was feasible and safe and that  
the number of Tregs in peripheral blood was reduced by a single cycle of CTX. 
Although in this report we will focus on the clinical results, the relevant 
immunological data will be presented. Significant increases in immune 
responsiveness were established, and overall survival was encouraging, with 
seven of the ten patients surviving ≥24 months. Some of the results of the present 
study have been previously reported in the form of an abstract(12).  
 
Materials and Methods 
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Study design  
The study was approved by the institutional ethical committee of the Erasmus MC 
(MEC-2008-109) and the Central Committee on Research involving Human 
Subjects (CCMO; NL24050-000-08) as defined by the WMO (Medical Research 
Involving Human Subjects Act). Procedures followed were in accordance with the 
ethical standards of these committees on human experimentation and with the 
Helsinki Declaration of 1975, as revised in 2008. The study is registered at 
http://www.clinicaltrials.gov with identifier NCT01241682.  
Patients with a suspicion of MPM and treatment-naive patients who had already 
been diagnosed with MPM were requested to give informed consent for isolating 
and storing pleural effusion cells if a medical indication was present to perform a 
pleural tap. Patients underwent standard treatment consisting of 4 to 6 courses of 
chemotherapy with either pemetrexed-cisplatin or pemetrexed-carboplatin. 
Response was assessed according to modified RECIST criteria(13).  
Patients with either partial response or stable disease were evaluated for study 
treatment with DC-based immunotherapy. In case of progressive disease after 
chemotherapy, patients were excluded from participation and treated according to 
the clinicians’ and patient’s decision. It is general practice in our reference center 
to consider patients for a pleurectomy/decortication (P/D) only after completion of 
chemotherapy, in case of persistent complaints, e.g. dyspnea, related to tumor 
load. P/D is only performed in patients who are fit for operation and in whom a 
macroscopic debulking is considered feasible according to published guidelines.  
DC-based immunotherapy in combination with low dose CTX was planned 8 to 
10 weeks after completion of the most recent cytoreductive therapy, i.e. either 
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chemotherapy or surgery (figure 1). During treatment, blood and serum samples 
were taken from each participant at regular intervals. The blood samples were 
tested for immunological responses, liver function and renal function. In addition, 
the serum samples were screened for the development of auto-immunity. Overall 
survival was defined as survival after date of diagnosis. Final survival data was 
gathered in August 2015. 
The study endpoints were (1) the reduction of regulatory T cells in the blood of 
patients after CTX, and (2), the safety and efficacy of the combination therapy 
consisting of DC vaccinations and CTX in MPM patients. 
 
Patient eligibility 
Signed written informed consent was obtained from each patient. At the time of 
diagnosis, patients were eligible for the study if they had an Eastern Cooperative 
Oncology Group (ECOG) performance status of 0 or 1 and acceptable vital organ 
functions. Patients were included if sufficient (> 150x106) tumor cells could be 
obtained from the pleural effusion or tumor biopsy material at the time of 
diagnosis. Patients were eligible if their serum was tested negative for infectious 
agents (human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV) 
I&II, hepatitis B virus (HBV), hepatitis C virus (HCV) and lues). Also, patients had 
to be negative for autoimmune disease and were tested for antinuclear antibodies 
(ANA), extractable nuclear antigens (ENA), and rheumatoid factors (RF). Delayed 
type hypersensitivity (DTH) skin tests were performed to investigate if the 
chemotherapeutic agents still exerted their influence on the patient’s immune 
system. A solution of 3.75 Lf of purified tetanus toxoid (NVI, Bilthoven, The 
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Netherlands) was used as positive control and 25 µl 0.9% saline as negative 
control. Reactivity to tetanus toxoid was measured in all the included patients 48 
hours after subcutaneous injection (induration > 5 mm) and was regarded as 
evidence for cellular immune competence. 
 
Dendritic cell vaccination and cyclophosphamide intake  
Eligible patients underwent immunotherapy based on loaded DCs in combination 
with low dose CTX. The tumor lysate that was used for loading of the DCs was 
obtained from pleural fluid in the non-surgical patients. In the surgical patients, 
the resection material was used for DC loading (see supplementary data).  
Patients received at least three immunizations with mature DC loaded with 
autologous tumor lysate and KLH with a 2-week interval (Figure 1). Six and 
twelve months after the third DC vaccination, a revaccination was given to boost 
the immune system if enough dendritic cells were available (4th / 5th 
vaccination)(Table 2). Each immunization, consisting of 50x10
6
 dendritic cells, 
was administered intradermally (i.d.) and intravenously (i.v.). Dosage was divided 
into 1/3 administered i.d. in the forearm and 2/3 administered i.v.. Blood pressure, 
body temperature, and oxygen saturation were constantly monitored till 2-h after 
the administration of vaccine therapy.  
Patients were treated with 2 times 50 mg tablet/day of CTX (Endoxan; Baxter 
B.V., Utrecht, The Netherlands) starting one week before vaccination to the day 
of every vaccination (followed by a week interval (figure 1)). The patients were 
asked to take the medication 2 hours after breakfast and dinner and to increase 
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their fluid intake by drinking extra water or other non-caffeinated beverages 
during the day. Urine of patients was routinely checked for signs of hematuria. 
 
Results 
 
Patients 
Between September 2009 and November 2011, 10 patients with advanced MPM 
and stable disease or response after chemotherapy were enrolled in the study. 
Patient characteristics are summarized in table 1. Nine patients commenced 
treatment within 6 weeks of diagnosis, and 1 patient opted for a delayed start of 
treatment (5 months). Five patients underwent an additional 
pleurectomy/decortication (table 2) before immunotherapy. One patient, patient 7, 
was included in spite of previous treatment with several lines of therapy, because 
of a long interval between the last treatment and recurrence of the disease, for 
which renewed treatment was initiated. After pleurectomy/decortication was 
performed, he was treated in the study. The survival post-surgery is used in this 
study.  
 
Clinical response evaluation 
Radiographic responses performed after the third vaccination are shown in table 
2. Of the 5 non-surgical patients, 4 had SD and 1 had CR after DC therapy. In 3 
of the surgically treated patients, the disease could not be evaluated, because 
surgery led to a macroscopic CR. However, 2 surgical patients presented with 
new lesions after DC therapy and therefore had PD. Therefore, in total, disease 
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control (no remaining evaluable disease, CR, PR and SD) was achieved in 8 out 
of 10 patients. In addition, table 2 shows the overall survival of the patients with a 
follow up time of 6 years. Seven of the 10 patients had a survival of ≥ 24 months 
(table 2 and figure 2). In August 2015, 2 patients were still alive, 1 of whom was 
in complete remission 66 months after diagnosis, and in the other the disease 
was very slowly progressive 50 months after diagnosis.  
 
Figure 3 shows the CT scans of a surgically treated patient, a 35-year-old woman 
(patient 5) who presented with two pleural masses with no radiographic response 
to cisplatin-pemetrexed treatment. A successful pleurectomy/decortication was 
performed after induction chemotherapy, and pathological evaluation of the tumor 
revealed a largely vital tumor with only 20% signs of necrosis, compatible with the 
radiographic finding of SD after chemotherapy. Furthermore, the tumor extended 
into the resected margins. Five injections of adjuvant DC therapy were given and 
no disease recurrence has been seen yet, 66 months after initiation of treatment. 
 
Safety and toxicity 
None of the 10 patients withdrew from the study. There were no logistic problems 
or practical problems in the preparation process, so all vaccinations were given 
as planned. The safety and toxicity of the combination of a low dose CTX (orally) 
and tumor lysate-pulsed DCs injected intradermally and intravenously in patients 
with MPM were assessed. No related grade >3 toxicities were found in any of the 
patients. Table 3 presents a summary of the main adverse events not related to 
tumor progression. Injection of DCs was well tolerated without systemic toxicity, 
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except for transient fatigue and low-grade fever on the day of the DC injection. 
These symptoms normalized after one day. After DC injection, a local skin 
reaction in the form of erythema without induration was seen in more than half of 
the subjects. Subsequent vaccinations (second and third) gave a quicker and 
increased induration and erythema in all patients, suggesting that some form of 
immunity was induced. None of the study participants developed any clinical 
evidence of autoimmunity. One patient developed a cardiomyopathy 18 months 
after DC vaccination. This was deemed to be related to the previous cisplatin 
treatment. 
 
Treg numbers 
After the first dosage of metronomic CTX, the percentage of Tregs of total CD4 
cells significantly decreased from 9.43 (range 4.34-26.10) to 4.51 (range 0.27-
10.30) (p=0.02)(figure 4). The initial percentage of Tregs was elevated in 4 
patients, 2 surgical and 2 non-surgical, In one of these non-surgical patients, the 
level of Tregs was 28% of all CD4 cells. In 3 of these 4 patients, levels of Tregs 
decreased after seven days of low-dose CTX. There was no correlation between 
initial Treg levels or decrease and radiological response or survival. Also, no clear 
difference in Treg levels or decrease was established between surgical and non-
surgical patients in this small patient cohort.  
 
Immune responses 
In all patients, a comparison of pre-first-vaccine and post-third-vaccine serum 
samples showed a significant increase of antibodies reactive to the model antigen 
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KLH, both of the immunoglobulin (Ig)G and IgM isotype. No or very low numbers 
of KLH-specific antibodies were detected in undiluted serum of all patients before 
vaccination, illustrating the suitability of this antigen to determine the immune 
competence of the vaccine. Responses to KLH increased after the initial 3 
vaccinations were completed (data not shown). Three months after the third 
vaccination , KLH responses were evidently present in the 6 patients in whom it 
could be determined. This proves that a successful immune reaction was induced 
by the DC vaccinations (Figure 5).  
 
Skin DTH testing 
The DTH skin test was performed two weeks after the third vaccination and was 
evaluable in all patients. There were no skin reactions to saline as the negative 
control. All patients revealed a positive test (erythema and/or induration) to the 
control antigen tetanus toxoid as well as to KLH (5 µg), and to DC with KLH 
(5x106 cells). This test proves that an effective immune response against KLH can 
be induced by DC vaccination. Eight patients tested positive to tumor lysate 
loaded DC (5x106 cells).  
In 6 patients, there was sufficient tumor material left for a post vaccination skin 
test with solely autologous tumor lysate (10 µg), and 2 of these patients developed 
a positive DTH test.  The 2 patients that revealed a negative skin test to both 
tumor lysate and tumor lysate loaded DCs were the patients with progressive 
disease after DC vaccination and the shortest survival.  
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Discussion 
 
In this study, we showed that combination treatment with CTX and DC 
immunotherapy is safe and feasible as a maintenance treatment in patients with 
mesothelioma after chemotherapy. The endpoint of the study was met with a 
significant decrease of Treg percentage of CD4 cells in blood of patients with 
increased levels. Radiographic tumor responses could not be established in all 
patients, as no measurable disease was present in the 5 surgical patients at 
inclusion in the trial. In the 5 non-surgical patients, one radiographic partial 
response was found. Overall disease control was found in 8 of the 10 patients, 
with 2 patients showing progression of disease. Overall survival was promising 
given the poor prognosis of this patient population. Considering the 
methodological flaws in this kind of comparison, overall survival was superior to a 
historical control group (data not shown), and also to published data(14–16). 
The role of surgery in mesothelioma is under debate(17, 18). This is due to 
disease recurrences after surgery. Therefore, an effective adjuvant treatment is of 
the utmost importance. Animal models have shown that resection of an 
established primary tumor reduced the tumor-associated immune suppressive 
environment(19). This theoretically supports the combination of surgery and 
immunotherapeutic strategies. Our data confirm that this combination is feasible 
and should be studied further. 
The addition of CTX resulted in a decrease in the percentage Tregs of total 
blood CD4 cells in most patients during CTX treatment, independent of the initial 
Treg percentage. This reduction was also found in previous studies with a similar 
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metronomic low-dose schedule(20, 21). By contrast, single dose and twice-a-
week dosing of CTX did not show an effect on Treg numbers(22, 23). Whether 
the decrease in Treg percentage caused an increased immune response cannot 
be concluded from these data, as no control group was included. The results 
found in this study are similar to our earlier murine experiments with DC 
immunotherapy and CTX(11). In that study, we did find survival to be increased 
when Treg levels were reduced.  
The fact that we found normal peripheral blood Treg percentages in a 
significant number of patients may be a reflection of patient selection, since we 
selected patients who were non-progressing or responding to chemotherapy. It 
cannot be determined from our data whether Treg levels do play a role in these 
patients. It cannot be excluded that in the patients with normal Treg other 
immunosuppressive mechanisms are more prominent, such as M2 tumor-
associated macrophages (TAMs) or myeloid derived suppressor cells (MSDCs). 
This finding could thus be of importance for personalizing immunotherapy. In this 
small study, no relations were established between initial Treg percentage or 
decrease in Tregs and radiologic response and overall survival. This can be due 
to the small sample size, but it is also possible that the number of circulating 
Tregs is not indicative of the Treg numbers within the tumor.  
The DTH skin test proves that an effective immune response to KLH can 
be induced by DC vaccination, but this test was not positive for tumor lysate 
and/or tumor lysate loaded DCs in all patients. Although the number of patients is 
too small to draw any definite conclusion, the 2 patients that experienced 
progressive disease after DC vaccination and had the shortest survival had 
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shown a negative skin test for both tumor lysate and tumor lysate loaded DCs. 
Therefore, the skin test should be evaluated in a larger cohort of patients as a 
marker for the outcome of DC vaccination therapy.  
Serum KLH responses were seen in all patients, but only after completion 
of the third vaccination. In our previous trial, responses were already present after 
the first vaccination(5). This difference is likely due to the suppressive effect of 
CTX on B cells(24). This is subject for further study.  
Another subject for further research is the impact of the 
immunosuppressive environment created by the tumor. This has now been 
shown to be both complex and subject to dynamic changes over time. Immune 
checkpoint pathways like CTLA-4 and PD-1 pathways negatively influence the 
immune response, and anti-CTLA4 antibodies showed clinical efficacy in patients 
with mesothelioma(25). Theoretically there might be a role for combining DC 
immunotherapy with these antibodies to increase the number of responding 
patients. However, other studies as well as our own have shown that the immune 
system is negatively impacted by immunosuppressive cells other than Tregs, 
such as M2 TAMs and MDSCs. These immunosuppressive cells negatively 
interact with checkpoint inhibitory therapy and with DC treatment(26, 27). 
Theoretically, decreasing the number of these cells may enhance the efficacy of 
checkpoint inhibition and DC treatment.  
This study has some limitations. First, the number of patients included in 
this study is rather limited due to the considerable costs and labor involved in the 
production of the DC vaccination therapy. Furthermore, our study group was a 
heterogeneous group with different subhistologies, different stages of disease 
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and different initial therapeutic approaches (e.g. surgical and non-surgical cases). 
Also, due to lack of randomization, the possibility of selection bias was present. 
While this did not seem to have an effect on the primary outcome of our study 
(Treg reduction and feasibility), it could have had an effect on the survival data. 
Second, while radiographic CT scanning was performed, no PET scans 
were done. An earlier trial with immunotherapy showed a decrease in tumor FDG 
uptake(28, 29). Although the immune responses generated could also increase 
FDG-activity via the influx of immune cells, as has been suggested recently(30), 
PET-imaging could have yielded additional information. 
Third, in the non-surgery group the autologous tumor lysate used for 
antigen loading of dendritic cells originated from treatment-naïve patients, while in 
the surgery group the tumor lysate was prepared from resected material derived 
from patients who had received chemotherapy as an induction to their surgery,  
which means that the tumor had already been treated. Three patients in the 
surgical group showed a prolonged survival, but selection bias should be 
considered. In addition, the 2 other surgical patients showed PD. The numbers of 
our study are too small to draw conclusions on this subject, but this will be 
addressed in future studies. 
Fourth, the efficacy of CTX on the suppression of Tregs was assessed by 
measuring the Treg values in peripheral blood. While this way of studying Tregs 
is the most convenient method for the patient, Treg levels in peripheral blood 
might not be representative for the Treg density at the tumor site(31, 32). 
However, in mesothelioma, repeat biopsies are only feasible in selected patients. 
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Fifth, although unlikely, we cannot rule out the possibility that 
leukapheresis has a temporary influence on the Treg numbers. Baseline values 
of Tregs were obtained at screening, before leukapheresis, while the Treg 
samples after CTX treatment were obtained after leukapheresis. To our 
knowledge, the impact of leukapheresis on Treg count is unknown. In 4 patients 
treated with DC vaccination, a total blood count including leucocyte differentiation 
was available at the 2 time points at which Tregs were measured, and these 
showed no change in leucocyte count or shift in leucocyte differentiation. Also, 
CTX was able to reduce Treg counts in previous studies without leukapheresis 
attributing the Treg decrease to CTX alone(9, 21). 
 
 
Conclusions of the study 
 
Short-term (1 week) treatment with a low-dose of CTX significantly reduced the 
mean Treg percentage of the total CD4 cells in peripheral blood, independent of 
initial Treg numbers. No correlation could be detected between the decrease in 
Treg and the response or overall survival. DC vaccination therapy in combination 
with low dose metronomic CTX is safe and feasible in patients with mesothelioma 
and no significant adverse effects were observed. Also, DC vaccination therapy 
proved to be feasible after debulking surgery. DC vaccination therapy combined 
with CTX resulted in radiographic disease control in 8 of the 10 patients. Overall 
survival was promising, with 7 out of 10 patients surviving ≥ 24 months and two 
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patients still alive 50 and 66 months after diagnosis. These outcomes warrant 
further study of this form of therapy in a larger, controlled trial. 
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Tables 
 
Patient No. Gender Age a Tumor subtype b TNM stage ECOG ps c  
1 Male 62 Epithelioid T1bN2M0 0 
2 Female 55 Biphasic** T2N0M0 0 
3 Male 63 Epithelioid T1bN0M0 1 
4 Male 71 Epithelioid T2N0M0 0 
5 Female 35* Epithelioid T1bN0M0 0 
6 Male 58 Biphasic** T1bN0M0 1 
7 Male 48 Epithelioid T3N0M0 0 
8  Male 78 Epithelioid T4N2M0 1 
9 Male 55 Epithelioid T1b0M0 0 
10  Male 75 Epithelioid T1aN0M0 1 
 
Table 1. Characteristics of the ten included MPM patients at time of diagnosis. 
a Patient age in years; b Histological tumor subtype by microscopic examination; c WHO 
ps = World Health Organisation performance status * Exposed as a child to high 
concentrations of asbestos by playing on a farmyard paved with asbestos.** Biphasic 
mesothelioma subtype is made up of both epithelioid cells and sarcomatoid cells.  
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Patient 
No. 
Chemo-
therapy 
Response 
on chemo- 
therapy 
Surgical 
resection 
Number 
of DC 
vaccina-
tions 
Response 
to DC-
based 
immuno-
therapy 
Overall Survival 
(months) 
1 4xCDDP-PEM SD No 4 x SD 24 DOD 
2 4xCDDP-PEM PR Yes 6 x NA 59 DOD 
3 
4xCBDCA-
PEM 
SD Yes 3 x PD 20 DOD 
4 
4xCBDCA-
PEM 
SD No 6 x SD 25 DOD 
5 4xCDDP-PEM SD Yes 5 x NA 66 AWD 
6 4xCDDP-PEM PR Yes 3 x PD 12 DOD 
7 
6xCDDP-
PEM* 
PR Yes 3 x NA 41** DOD 
8 
4xCBDCA-
PEM 
SD No 4 x SD 14 DOD 
9 4xCDDP-PEM PR No 3 x CR 50 AWD 
10 4xCDDP-PEM SD No 3 x SD 27 DOD 
 
Table 2. Radiographic responses to chemotherapy and DC-based immunotherapy 
treatment, number of DC vaccinations and overall survival. 
CDDP = cisplatin, CBDCA = carboplatin, PEM= pemetrexed 
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DOD = Died of disease; AWD = Alive with disease (as of August 2015) 
*Additional previous therapy prior to pleurectomy/decortication consisted of zoledronic 
acid, intrapleural gene therapy(33), gemcitabine with and without cisplatin alternating 
with cyclophosphamide.  
** Survival post pleurectomy/decortication, OS after diagnosis was 83 months. 
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 Grade 1 Grade 2 Grade 3 Grade 4 
Fever 4 1 0 0 
Nausea 4 0 0 0 
Rash 3 0 0 0 
Thoracic pain 3 0 0 0 
Lethargy 3 0 0 0 
Dyspnoea 2 0 0 0 
Depression 0 1 0 0 
Diarrhea 1 0 0 0 
Cardiomyopathy 0 0 1 0 
Abdominal pain 1 0 0 0 
 
Table 3. Adverse events 
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Figures  
 
Figure 1: Schematic representation of the treatment procedure. A 4th and 5th 
vaccination, after 6 or 12 months after the last DC vaccine, was given if enough 
dendritic cells were available. 
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Figure 2. Kaplan-Meier plot of overall survival for all evaluable patients in the study. At the last follow-up 
on August 2015, 2 of 10 patients were still alive. 
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Figure 3. Sustained response in a surgical patient. (A) Before any treatment, two 
pleural masses are visible on the CT scan; one dorsally next to the spine and the other 
on the diaphragm. CT scan after chemotherapy showed stable disease (not shown). 
(B) After pleurectomy/decortication and DC administration, the cranial lesion is not 
visible and slight post-surgery abnormalities are visible. Caudally, due to post-surgery 
changes, it is difficult to detect any tumor. (C) 48 Months after DC treatment, no pleural 
masses are visible either cranially or caudally. 
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Figure 4. Measuring Tregs (CD3+CD4+CD25+FoxP3+CD127- cells) in blood samples 
of patients before CTX treatment and after the first week of metronomic CTX showed a 
significant decrease of the mean Treg percentage of total CD4 cells (P=0.02) (A). (B) 
The individual Treg differences before and after the first CTX administration show a 
decrease in nine out of ten patients.  
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Figure 5. KLH-specific IgG increases after DC-based immunotherapy. Kinetics of IgG 
responses against KLH was measured in serially diluted serum of all patients during 
treatment and of seven patients following treatment. In patient 3 and 6, no post-
treatment is available due to the deteriorating clinical condition of these patients with 
progressive disease. In patient 7, serum samples were unavailable at the specified time 
point because the patient was living abroad. Post-treatment increase of KLH specific 
IgG was evident in all measured samples. IgM levels (not shown) mirrored IgG levels. 
Pre Tre= four weeks before CTX / DC treatment; Post Tre= 3 months after CTX / DC 
treatment.  
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Supplemental data 
 
Preparation of tumor lysate for DC loading 
Isolation and preparation of autologous tumor lysate for DC loading was 
performed as described earlier(5). Tumor tissue (cases 2, 3, 5, 6, and 7) was 
removed by debulking surgery (pleurectomy/decortication), placed in phosphate-
buffered saline (PBS) in sterile containers and transported immediately to the 
cleanroom facility. Representative tumor pieces were embedded in Tissue-Tek II 
optimum cutting temperature ([OCT] Miles, Naperville, IL, USA), snap-frozen and 
stored at –80 °C. Remaining tumor tissue was dispersed to create a single cell 
suspension. In case of pleural effusions (cases 1, 4, 8, 9, and 10), fluid was 
aspirated and collected in sterile flasks without anticoagulant or other additives. 
Effusions were transported immediately to the cleanroom facility and centrifuged 
at 400xg for 15 min at room temperature (RT). If necessary, small or large 
amounts of red blood cells in the cell pellet were removed by hypotonic lysis using 
sterile water or Ficoll-Paque PREMIUM, respectively. Cells were counted and 
resuspended at a concentration of 50x106 / ml in PBS. Cytospin preparations 
and/or tumor sections were prepared and examined for the presence of tumor 
cells using the following antibodies: cytokeratin 5/6, cytokeratin 19, 
thrombomodulin, N-cadherin, vimentin, HBME-1, calretinin, and Wilms’ tumor 1 
(WT-1) protein (all DAKO, Glostrup, Denmark). Total numbers of malignant cells 
exceeded 150x106 cells, and the percentage was at least 30% of total cells 
(inclusion criteria); in the case of biopsy material, total wet weight was at least 0.2 
gram showing >30% positivity for tumor markers. Remaining cells were lysed by 
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six cycles of freezing in liquid nitrogen and thawing at room temperature followed 
by 100 Gy of irradiation. Large particles were removed by centrifugation (5 min, 
200xg), and supernatants were passed through a 0.45 µm filter. The resulting 
tumor lysates were stored in aliquots at –80°C until use.  
 
Dendritic cell culture 
We used our previously described method to generate clinical-grade mature 
dendritic cells in conformity with Good Manufacturing Practice (GMP) 
guidelines(5). In brief, concentrated 120 to 150 ml leukocyte fractions were 
generated through a 4-h restricted peripheral blood leukapheresis, processing on 
average 9L of blood (COBE Spectra Apheresis System, Gambro BCT, Zaventem, 
Belgium). Peripheral blood mononuclear cells were then enriched using counter-
flow centrifugal elutriation (Elutra, Gambro BCT, Zaventem, Belgium) as 
described by Berger et al.(34). In 60% of the cases, the percentages of 
contaminating granulocytes in the enriched monocyte fractions after counter-flow 
centrifugal elutriation were below 10%. A density gradient centrifugation was 
routinely performed on all samples to remove the granulocytes before starting the 
culturing process. In this way, the percentages of granulocytes at the start of the 
procedure were always below 8% for all preparations. Monocytes were 
resuspended at a concentration of 5x10
6
 cells/ml in XVIVO-15 (Cambrex Bio 
Science, Verviers, Belgium) supplemented with 2% pooled human AB serum 
(DC-culture medium [DC-CM]). The next day, half of the medium was removed 
and replaced by the same volume of DC-CM supplemented with 1000 IU/ml 
interleukin (IL)-4 (CellGenix, Freiburg, Germany) and 1600 IU/ml granulocyte 
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macrophage-colony stimulating factor (GM-CSF; CellGenix). After 5 days of 
culture, semi-adherent and non-adherent cells were harvested by pipetting. Cells 
(1x10
6
) were seeded per well of a 6-well plate in fresh DC-CM supplemented with 
tumor cell lysate (1 tumor cell equivalent to 3 DC), 500 IU/ml IL-4, 800 IU/ml GM-
CSF, and 10 µg/ml keyhole limpet hemocyanin (KLH) (Calbiochem, La Jolla, CA, 
USA). The immune competence was monitored by means of co-loading with the 
protein KLH, a foreign protein that stimulates T-helper responses. On day 8, the 
maturation cocktail was added (prostaglandin E2 [PGE2 Prostin E2; 10 µg/ml 
Pharmacia&Upjohn, Puurs, Belgium], tumor necrosis factor-alpha [TNF-α, 20 
ng/ml), interleukin (IL)-1β [5 ng/ml], and IL-6 [15 ng/ml; all CellGenix]). Cells were 
harvested at day 10 and 50x10
6
 cells were used for immediate vaccination; the 
remaining cells were cryopreserved in DMSO for later vaccinations (55x10
6
 cells 
per vial) and for DTH skin testing. Loaded DC are defined as an advanced 
therapy medicinal product (ATMP) and released for vaccination after thorough 
check by accredited qualified person according to the Clinical Trials Directive 
(2001/20/EC). These include consistency and quality in the processing steps and 
final products and check of the manufacturing facility, among others. The vaccine 
was routinely analyzed for DC purity and tested for infectious agents before 
administration to patients. Several quality control tests were performed before the 
cellular vaccine was released.  
 
Flow cytometric analysis of clinical-grade DC 
An aliquot of the vaccine preparation was retained to examine the expression of 
extracellular markers. The following monoclonal antibodies were purchased from 
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BD Biosciences / BD Pharmingen (Erembodegem, Belgium): FITC-conjugated 
CD86 and CD195, PE-conjugated CD83 and CD-95, CD80 - PE-Cy5, CD209 - 
PerCP-Cy5.5, CD11c - APC, and APC-Cy7 conjugated HLA-DR. The specificity of 
the antibodies was checked using equivalent concentrations of fluorochrome- and 
isotype-matched negative control immunoglobulins. Cells were washed with FACS 
buffer (PBS supplemented with 0.25 % BSA, 0.5 mM EDTA, and 0.05% sodium 
azide) and counted. At least 0.4x106 cells in 100 µl were stained with appropriate 
dilutions of antibodies. Cells were incubated on ice for 30 min in the dark, washed 
twice with FACS buffer and analysed by means of LSR flow cytometry (BD 
Biosciences). Release criteria for each batch of DC were sterility testing (negative 
for aerobic or anaerobic microorganisms), viability (>80% viable by flowcytometry 
and propidium iodide or 7-aminoactinomycin D [7-AAD]), purity (>95% CD11c+ 
MHC class II+), maturation (>60% of CD80 expression) and stability after freezing.  
 
Delayed type hypersensitivity skin test 
To assess the patient’s immunocompetence, DTH skin testing was performed one 
week before the apheresis by means of intradermal application of tetanus toxoid 
(positive control) and a physiological salt solution (negative control) on the ventral 
surface of the patient’s forearm. If this did not result in a response to tetanus that 
could be related to the effects of chemotherapy, apheresis was postponed and the 
skin DTH test was repeated two weeks later. If the second test was also negative 
the patient was excluded from participation in the study. A DTH skin test was also 
performed two weeks after the third vaccination; it was further completed with 
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autologous tumor lysate (10 µg), KLH (5 µg), tumor lysate loaded DC with or 
without KLH (both 5x106 cells). DTH responses were evaluated after 48 h.  
 
Immune response assessment against KLH  
Serum samples were collected into SST serum separation tubes (BD biosciences) 
before, during, and in the lifelong clinical follow-up of the patients. After allowing 
the serum 30 min to clot, tubes were centrifuged 10 min at 1000 x g. Serum was 
collected, aliquoted and stored at –80 °C until use. Humoral responses to KLH 
were measured in the serum of patients by ELISA. Microtiter plates (96 wells) 
were coated overnight at 4 °C with 25 µg/ml KLH in PBS per well. After blocking 
the plates with 1% powdered milk in PBS, different concentrations of patient 
serum (range, 1 in 100 to 1 in 500,000) were added for 1 h at room temperature. 
After extensive washing, specific anti-human IgG or anti-human IgM conjugated 
with horseradish peroxidase were allowed to bind for 1 h at room temperature. 
Peroxidase activity was revealed with the use of 3,3'5,5-tetramethyl-benzidine 
(TMB) as substrate, and absorbance was measured in a microtiter plate reader 
(VersaMax, Molecular Devices, Sunnyvale, CA, USA).  
 
Treg analysis 
Blood samples obtained before the treatment protocol and at the first vaccination 
(after induction cyclophosphamide) were analyzed. Tregs were defined as CD3+, 
CD4+, CD25+, FoxP3+, and CD127-. Before immune staining, the cells were 
stained for viability using LIVE/DEAD Fixable Aqua Dead Cell Stain (Invitrogen 
life technologies) in PBS. Subsequently the cells were washed in FACS buffer 
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and incubated 30 min at 4ºC with APC-eF780 labeled anti-CD3 (Clone UCHT1; 
eBioscience), AF700-labeled anti-CD4 (Clone RPA-T4; eBioscience), PE-Cy7-
labeled anti-CD25 (Clone MA251; BD Biosciences), V450-labeled anti-CD127 
(Clone hIL7R-M2; BD Biosciences), PE-TexasRed-labeled anti-CD45RA (Clone 
MEM-56; Invitrogen life technologies), FITC-labeled anti-CCR7 (Clone 150503; 
R&D Systems, Abingdon, UK) and BV605-labeled anti-CCR4 (Clone 1G1; BD 
Biosciences). Thereafter the cells were washed, fixated, and permeabilized using 
the eBioscience FoxP3 kit, and the cells were stained intracellularly with PE-
labeled anti-FoxP3 (Clone 236A/E7; eBioscience), APC-labeled anti-Ki-67 (Clone 
20Raj1; eBioscience) and PerCP-eF710-labeled anti-CTLA-4 (Clone 14D3; 
eBioscience). Before analysis, the cells were washed with FACS buffer. The 
samples were measured on an LSR-II flow cytometer (BD Biosciences), and data 
analysis was performed using FlowJo software. 
 
Statistical analysis 
Mean Treg percentage was compared before and after CTX administration and p 
values were calculated with the Wilcoxon signed-rank test. Statistical calculations 
were performed using IBM SPSS Statistics 21. Statistical significance was 
established at the p < 0.05 level, and analysis was two-sided. 
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